CLINICAL_TRIALS
trial_result
· 2026-02-06
Clinical Trial Update: CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia [Phase 3]
Summary
The Phase 3 CONNEX-3 trial evaluating Iclepertin for improving learning and memory in schizophrenia has completed and posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED | Results posted: 2026-02-06